Background and Scope
GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, liraglutide, dulaglutide and tirzepatide — have become among the most widely prescribed and discussed drug classes in metabolic medicine. Their approval for type 2 diabetes management, subsequent approval for obesity, and emerging evidence across cardiovascular, renal and hepatic endpoints have positioned them as a potential cornerstone of metabolic disease treatment.[1]
This article critically evaluates the published evidence for GLP-1 RAs: their pharmacological mechanism, the quality and limitations of the clinical trial data supporting their use, their documented adverse effects, and the evidence base for a functional medicine approach as an adjunct — not an alternative — to pharmacological management of metabolic disease.
All clinical claims in this article are referenced to peer-reviewed published literature. Where trial data is cited, study design limitations are noted.
Pharmacology: Mechanism of Action
Glucagon-like peptide-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Endogenous GLP-1 has a plasma half-life of approximately 1–2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical GLP-1 RAs are structurally modified analogues resistant to DPP-4 degradation, with half-lives of hours to days depending on formulation.[2]
GLP-1 RAs act at GLP-1 receptors expressed across multiple tissues:
- Pancreatic beta cells: Stimulate glucose-dependent insulin secretion, reducing postprandial hyperglycaemia with low intrinsic hypoglycaemia risk
- Pancreatic alpha cells: Suppress glucagon secretion, reducing hepatic glucose output
- Gastric smooth muscle: Slow gastric emptying, attenuating postprandial glucose excursions
- Hypothalamus and brainstem: Activate satiety centres via direct receptor binding, reducing appetite and food intake
- Cardiovascular tissue: Direct anti-inflammatory and anti-atherogenic effects at the vascular endothelium — mechanism partially independent of weight loss[3]
- Liver and adipose tissue: Reduce hepatic lipogenesis and promote lipolysis
- Kidneys: Reduce glomerular hyperfiltration and oxidative stress
Tirzepatide (Mounjaro) acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP receptor agonism provides additive insulinotropic effects and may contribute to superior weight loss outcomes observed with tirzepatide compared to GLP-1 agonism alone.[4]
Clinical Evidence: What the Trials Show
Glycaemic Control in Type 2 Diabetes
The SUSTAIN trial programme (semaglutide vs. comparators in T2DM, n=8,416 across 7 trials) demonstrated HbA1c reductions of 1.1–1.6% with semaglutide 1mg versus 0.4–0.9% with comparators including sitagliptin, exenatide ER and insulin glargine. Body weight reductions of 3.5–6.5kg were observed.[5]
The SUSTAIN trials were industry-sponsored (Novo Nordisk). Active comparators varied between trials, limiting direct comparison. Follow-up periods ranged from 30–56 weeks — insufficient to assess long-term durability of effect or safety signals requiring extended observation. Most trials excluded patients with eGFR <30 and those with significant comorbidities, reducing external validity for complex real-world patients.
Weight Reduction in Obesity
The STEP trial programme assessed semaglutide 2.4mg weekly in adults with BMI ≥30 (or ≥27 with comorbidity) without diabetes. STEP 1 (n=1,961) demonstrated a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo. STEP 5 extended follow-up to 104 weeks, maintaining 15.2% weight reduction.[6]
The SURMOUNT-1 trial (tirzepatide, n=2,539) demonstrated mean weight reductions of 15.0%, 19.5% and 20.9% at the 5mg, 10mg and 15mg doses respectively at 72 weeks — representing the largest pharmacologically induced weight loss documented in a randomised controlled trial to date.[7]
STEP and SURMOUNT trials are industry-sponsored. Crucially, body composition was not comprehensively reported as a primary endpoint — total weight loss obscures the ratio of fat mass to lean mass lost. Subsidiary analyses suggest 25–40% of weight lost may be lean mass (skeletal muscle), with implications for long-term metabolic health that were not primary endpoints of these trials.[8] Long-term safety data beyond 2 years remains limited for most agents.
Cardiovascular Outcomes
The LEADER trial (liraglutide, n=9,340, median 3.8 years) demonstrated a significant reduction in MACE (major adverse cardiovascular events) — HR 0.87 (95% CI 0.78–0.97) — in patients with T2DM and high cardiovascular risk.[9] The SUSTAIN-6 trial (semaglutide) showed HR 0.74 (95% CI 0.58–0.95) for MACE.[10]
The SELECT trial (2023, semaglutide 2.4mg, n=17,604) is the most significant recent development: a 20% reduction in MACE in patients with established cardiovascular disease and obesity without diabetes (HR 0.80, 95% CI 0.72–0.90, p<0.001), over a mean 33.3 months.[11]
SELECT is a landmark trial but requires contextualisation. The absolute risk reduction was 1.5% (NNT approximately 67 over ~3 years). All cardiovascular outcome trials enrolled patients with established or high-risk cardiovascular disease — findings cannot be extrapolated to lower-risk populations. The mechanism of cardiovascular benefit remains partially unclear: direct GLP-1 receptor effects at the vasculature, weight loss, glycaemic improvement and anti-inflammatory effects likely all contribute but have not been isolated.
Renal Outcomes
The FLOW trial (semaglutide in CKD with T2DM, n=3,533) was stopped early at interim analysis after demonstrating a 24% reduction in the composite renal endpoint (sustained ≥50% eGFR decline, ESKD, renal or cardiovascular death) — HR 0.76 (95% CI 0.66–0.88).[12] This represents the first CVOT to demonstrate GLP-1 RA renal protection as a primary endpoint.
Hepatic Outcomes
The LEAN trial (liraglutide in NASH, n=52) demonstrated histological improvement in NASH activity score and fibrosis stage versus placebo at 48 weeks in a small but well-designed proof-of-concept RCT.[13] Larger Phase 3 trials are ongoing. Current hepatic data should be considered preliminary — not yet sufficient to support routine prescribing for NASH as a primary indication.
| Indication | Key Trial | Key Finding | Evidence Quality |
|---|---|---|---|
| T2DM glycaemia | SUSTAIN programme | HbA1c reduction 1.1–1.6% | Multiple RCTs · Industry-sponsored |
| Obesity | STEP 1, SURMOUNT-1 | 14.9–20.9% weight reduction | Large RCTs · Industry-sponsored |
| CV outcomes (T2DM) | LEADER, SUSTAIN-6 | MACE reduction HR 0.74–0.87 | Large RCTs · Robust |
| CV outcomes (obesity, no T2DM) | SELECT (2023) | MACE reduction HR 0.80 | Large RCT · Landmark |
| Renal outcomes | FLOW (2024) | Composite renal endpoint HR 0.76 | RCT stopped early at interim |
| Hepatic (NASH) | LEAN trial | Histological improvement | Small RCT n=52 · Preliminary |
| Neurological | Multiple Phase 2 | Signal in Parkinson's, Alzheimer's | Early-phase · Investigational only |
Adverse Effects: The Evidence
Adverse effect data from RCTs must be interpreted alongside the limitations of trial populations (exclusion of most complex comorbidities) and observation periods (typically under 2 years). Post-marketing surveillance continues to characterise the real-world safety profile of these agents.
Documented Benefits
- Low intrinsic hypoglycaemia risk (glucose-dependent mechanism)
- Blood pressure reduction (2–4 mmHg systolic in STEP 1)
- Improvement in triglyceride and HDL profiles
- Reduction in hsCRP (anti-inflammatory signal)
- Reduction in hepatic steatosis on imaging
- Cardiovascular and renal protection in high-risk groups
Documented Adverse Effects
- Gastrointestinal (nausea, vomiting, diarrhoea) — 30–45% incidence, usually dose-dependent and transient
- Lean mass loss — 25–40% of total weight lost estimated as lean tissue
- Cholelithiasis — increased gallstone risk with rapid weight loss
- Acute pancreatitis — rare but serious; incidence approximately 0.3% in LEADER
- Gastroparesis — clinically significant delayed gastric emptying in some patients
- Thyroid C-cell tumours — demonstrated in rodent models; human relevance uncertain; contraindicated in personal/family history of MTC or MEN2
- Rebound weight regain — STEP 4 withdrawal data: mean 11.6% weight regain within 52 weeks of cessation, with reversal of most cardiometabolic benefits
- Nutritional insufficiency risk from sustained reduced food intake
The lean mass loss finding warrants particular clinical attention. A 2023 post-hoc analysis of STEP trial data estimated that lean mass comprised 25–38% of total weight lost on semaglutide, with significant individual variability.[8] Skeletal muscle is the primary site of postprandial glucose disposal. Loss of skeletal muscle mass during weight loss may partially offset the metabolic benefits of adipose tissue reduction, particularly if weight is subsequently regained as fat rather than muscle — a phenomenon observed in post-bariatric populations.
No large RCT has used preservation of lean mass as a primary or co-primary endpoint. Body composition assessment (DEXA or equivalent) is not standard in GLP-1 RA trials. The clinical significance of lean mass loss at the individual patient level — and optimal strategies to mitigate it — remain inadequately studied in the published literature.
Rebound Weight Regain: The Cessation Problem
The STEP 4 trial (semaglutide withdrawal, n=803) is the most rigorous published data on what occurs after GLP-1 RA cessation. Participants who stopped semaglutide at week 20 regained a mean of 11.6% of body weight by week 68 (net loss 7.9% from baseline versus 17.4% in those continuing). Most cardiometabolic parameters — blood pressure, lipids, HbA1c — returned toward baseline values.[14]
This finding is consistent with the known pathophysiology: GLP-1 RAs reduce appetite by pharmacologically activating satiety signalling that is dysregulated in obesity. On cessation, this dysregulation is not corrected — the underlying hormonal and neurological drivers of excess appetite and energy storage reassert themselves. Weight regain is therefore a pharmacologically predictable consequence of cessation, not a patient compliance failure.
The Functional Medicine Evidence Base
The functional medicine approach to metabolic disease is grounded in identifying and addressing the upstream physiological drivers of metabolic dysfunction — as distinct from pharmacologically managing its downstream consequences. It is not proposed as a replacement for GLP-1 RA prescribing where indicated. It is proposed as a complementary framework that addresses mechanisms the drugs do not.
Dietary Pattern and Insulin Resistance
A 2020 systematic review and meta-analysis (Evert et al., published in Diabetes Care) found that low-carbohydrate dietary patterns reduced HbA1c by 0.5–1.0% and promoted weight loss of 3–4kg at 6–12 months in T2DM, with greatest effects in the short term.[15] Mediterranean dietary patterns reduced cardiovascular risk and improved glycaemic control in the PREDIMED trial (n=7,447), including a 30% reduction in MACE versus low-fat diet control.[16]
Resistance Exercise and Lean Mass
A 2018 meta-analysis (Stokes et al., Nutrients) confirmed the dose-response relationship between resistance training and skeletal muscle hypertrophy, with optimal protein intake of 1.6g/kg/day for muscle protein synthesis.[17] In the context of GLP-1 RA-induced lean mass loss, resistance exercise and optimised dietary protein are the evidence-based interventions to mitigate this adverse effect — neither of which are routinely integrated into standard GLP-1 prescribing pathways.
Gut Microbiome and Metabolic Function
A 2022 RCT (Dahl et al., Nature Medicine) demonstrated that gut microbiome composition predicts glycaemic response to dietary intervention, with individuals high in Prevotella copri showing superior glycaemic response to wholegrain diets. This suggests microbiome assessment could be clinically meaningful in personalising dietary interventions for metabolic disease.[18] However, the evidence base for specific probiotic or prebiotic interventions in T2DM remains insufficient for clinical recommendation at this stage.
Sleep and Metabolic Health
A 2022 RCT (Tasali et al., JAMA Internal Medicine) demonstrated that sleep extension in habitual short sleepers (mean increase from 6.4 to 8.0 hours) reduced daily energy intake by 270 kcal versus control, without dietary counselling. The mechanism involves normalisation of ghrelin and leptin signalling disrupted by sleep restriction.[19] This represents a non-pharmacological intervention targeting the same appetite dysregulation that GLP-1 RAs address pharmacologically.
Nutritional Insufficiency in Metabolic Disease
A systematic review (Barbagallo et al., 2019) found that magnesium deficiency is significantly associated with insulin resistance and T2DM, with evidence that oral magnesium supplementation improves insulin sensitivity in hypomagnesaemic individuals.[20] Given that reduced food intake on GLP-1 RAs increases the risk of micronutrient insufficiency, baseline and ongoing nutritional assessment is clinically warranted but not currently standard in GLP-1 prescribing protocols.
Where the Evidence Supports a Complementary Approach
The published evidence supports the following as clinically meaningful adjuncts to GLP-1 RA therapy: (1) resistance exercise and adequate protein intake to mitigate lean mass loss; (2) Mediterranean or low-carbohydrate dietary patterns for independent glycaemic and cardiovascular benefit; (3) sleep optimisation to address appetite dysregulation; (4) assessment and correction of nutritional insufficiencies arising from reduced food intake. These are not alternative treatments — they address mechanisms that GLP-1 RAs do not, and the evidence for their benefit in metabolic disease is independent and additive.
Conclusions and Clinical Implications
The evidence base for GLP-1 receptor agonists in metabolic disease is substantial and, in several domains, practice-changing. The cardiovascular outcome data (LEADER, SUSTAIN-6, SELECT) represents robust, large-scale evidence of clinical benefit beyond glycaemic control. The weight loss data from STEP and SURMOUNT trials documents a magnitude of pharmacologically induced weight reduction unprecedented outside surgical intervention.
However, critical evaluation of this evidence base reveals important limitations: industry sponsorship of most trials, exclusion of complex comorbid populations, inadequate characterisation of lean mass loss, and the well-documented rebound weight regain on cessation. These are not arguments against use — they are arguments for informed prescribing that accounts for these limitations.
The functional medicine evidence base supports a complementary framework addressing upstream drivers of metabolic dysfunction — dietary pattern, physical activity, sleep, nutritional status and gut health — that GLP-1 RAs do not address. The most clinically meaningful role for this approach, supported by the cessation data, is in building sustainable metabolic health that can outlast pharmacological intervention. The evidence for doing so alongside GLP-1 RA therapy, rather than as an alternative to it, is both logical and increasingly supported by the published literature.
